BeOne Medicines shared a post on LinkedIn: “News for Investors and Media: The FDA has granted our GPC3x4-1BB bispecific antibody Fast Track …
The FDA Has Granted BeOne’s Bispecific Antibody Fast Track Designation in HCC
Share This Story, Choose Your Platform!
About the Author: AJDesign77
